This site is intended for health professionals only

UCB, UCB Pharma and PDL have resolved all disputes


UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma SA (UCB), and PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL) today announced that the companies have agreed to resolve all legal disputes between them.

The definitive settlement agreement relates to all legal disputes, including those relating to UCB’s pegylated humanized antibody fragment, Cimzia® (certolizumab pegol) and PDL’s patents known as the Queen et al patents.

Under the settlement, PDL provided UCB with a covenant not to sue UCB for any royalties regarding UCB’s Cimzia® product under the Queen patent portfolio in return for a lump sum payment of US$ 10 million and the mutual resolution of other disputes between the two companies.

Other disputes include two patent interferences pending before the United States Patent and Trademark Office and a patent opposition in the European Patent Office.

No additional payments will be owed by UCB to PDL under the Queen patents in respect of Cimzia® sales for any indication and the sale of a product in development that may or may not be approved within the term of the Queen patents.

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine